Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$4.55 - $6.75 $358,658 - $532,075
-78,826 Reduced 57.61%
58,008 $295,000
Q4 2023

Feb 12, 2024

BUY
$5.04 - $9.95 $352,185 - $695,286
69,878 Added 104.36%
136,834 $1.27 Million
Q3 2023

Nov 14, 2023

SELL
$6.55 - $9.37 $9,117 - $13,043
-1,392 Reduced 2.04%
66,956 $438,000
Q2 2023

Aug 14, 2023

SELL
$7.66 - $9.5 $109,844 - $136,230
-14,340 Reduced 17.34%
68,348 $555,000
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $77,925 - $110,050
9,366 Added 12.77%
82,688 $708,000
Q4 2022

Feb 14, 2023

SELL
$7.65 - $14.43 $35,947 - $67,806
-4,699 Reduced 6.02%
73,322 $678,000
Q3 2022

Nov 14, 2022

SELL
$8.9 - $12.86 $1,361 - $1,967
-153 Reduced 0.2%
78,021 $805,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $12.84 $34,166 - $60,014
4,674 Added 6.36%
78,174 $783,000
Q1 2022

May 13, 2022

SELL
$9.74 - $17.69 $151,944 - $275,964
-15,600 Reduced 17.51%
73,500 $905,000
Q4 2021

Feb 11, 2022

SELL
$16.88 - $23.31 $35,448 - $48,951
-2,100 Reduced 2.3%
89,100 $1.55 Million
Q3 2021

Nov 12, 2021

BUY
$16.82 - $25.75 $8,410 - $12,875
500 Added 0.55%
91,200 $1.64 Million
Q2 2021

Aug 12, 2021

SELL
$10.16 - $28.86 $39,624 - $112,554
-3,900 Reduced 4.12%
90,700 $2.07 Million
Q1 2021

May 17, 2021

SELL
$5.17 - $16.13 $205,766 - $641,974
-39,800 Reduced 29.61%
94,600 $1.41 Million
Q4 2020

Feb 03, 2021

SELL
$4.01 - $7.58 $84,611 - $159,938
-21,100 Reduced 13.57%
134,400 $726,000
Q3 2020

Nov 16, 2020

BUY
$3.8 - $5.0 $590,900 - $777,500
155,500 New
155,500 $708,000
Q2 2018

Aug 03, 2018

SELL
$2.08 - $4.26 $60,320 - $123,540
-29,000 Closed
0 $0
Q3 2017

Nov 01, 2017

BUY
$3.42 - $4.87 $99,180 - $141,230
29,000
29,000 $118,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.